About: NanOlogy
Profile:
Posts by NanOlogy:
- NanOlogy Completes Enrollment of Bladder Cancer Clinical Trial (March 9, 2021 - Home Page, NanOlogy Press Release)
- NanOlogy Presents Results of SOR007 (Topical Submicron Particle Paclitaxel) Phase 1/2 Clinical Trial in the Treatment of Cutaneous Metastases at 2020 SABCS® (December 29, 2020 - NanOlogy Press Release)
- SABCS 2020 Poster: Phase 1/2 Clinical Trial of A Topical Submicron Particle Paclitaxel (SOR007) for the Treatment of Cutaneous Metastases (December 17, 2020 - Presentations)
- Drug Delivery and Translational Research: Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies (November 10, 2020 - Home Page, Publications)
- NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac® for Intratumoral Treatment of Prostate Cancer (November 4, 2020 - Home Page, NanOlogy Press Release)
- Gynecologic Oncology Reports: Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer surgery (September 17, 2020 - Home Page, Publications)
- ASCO 2020 Abstract: Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer undergoing cytoreductive surgery (July 2, 2020 - Presentations)
- NanOlogy Announces Initiation of a Lung Cancer Clinical Trial Following FDA Allowances of Two IND Applications for NanoPac® in Lung Cancer (June 9, 2020 - Home Page, NanOlogy Press Release)
- NanOlogy Presents Updated Clinical Data on Targeted Injections of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasms on DDW2020 Site (May 14, 2020 - NanOlogy Press Release)
- Digestive Disease Week 2020: Intracystic Injection of Submicron Particle Paclitaxel (SPP) for the Treatment of Mucinous Pancreatic Cystic Lesions Resulted in Reduction in Cyst Volume, an Interim Report (Mohamed O. Othman) (May 13, 2020 - Presentations)
- Digestive Disease Week 2020: EUS-guided Injection of Intratumoral Submicron Particle Paclitaxel (SPP) for the Treatment of Locally Advanced Pancreatic Adenocarcinoma (LAPC) – Phase 2 Study (Neil Sharma, MD) (May 13, 2020 - Presentations, Uncategorized)
- Investigational New Drugs: Intratumoral Submicron Particle Docetaxel Inhibits Syngeneic Renca Renal Cancer Growth & Increases CD4+, CD8+ and Treg Levels in Peripheral Blood (April 3, 2020 - Home Page, Publications)
- Current Urology Reports: Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage (January 9, 2020 - NanOlogy in the News)
- Video Highlights: NanoPac Injection for Pancreatic Cancer | Neil R. Sharma, MD, Parkview Cancer Institute (3-minute version) (November 10, 2019 - Presentations)
- NanOlogy Clinical Updates on Local Injection of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas (November 7, 2019 - Home Page, NanOlogy Press Release)
- Video: NanoPac Injection for Pancreatic Cancer | Neil R. Sharma, MD, Parkview Cancer Institute (7-minute version) (November 7, 2019 - Home Page, Presentations)
- ACG 2019 Plenary Presentation: A Novel EUS-guided Intratumoral Delivery of Submicron Particle Paclitaxel for the Treatment of Locally Advanced Pancreatic Cancer. (October 31, 2019 - Presentations)
- ACG 2019 Poster: NanoPac-2017-01 Mid-Study Report: Safety, Tolerability and Preliminary Efficacy of Intracyctic Submicron Particle Paclitaxel (SPP) for the Treatment of Pancreatic Mucinous Cysts (October 31, 2019 - Home Page, Presentations)
